Corline Biomedical AB (STO:CLBIO)
Sweden flag Sweden · Delayed Price · Currency is SEK
18.20
-0.10 (-0.55%)
May 22, 2026, 5:11 PM CET

Corline Biomedical AB Balance Sheet

Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Equivalents
32.920.5617.6717.0126.2141.64
Cash & Short-Term Investments
32.920.5617.6717.0126.2141.64
Cash Growth
180.38%16.35%3.86%-35.09%-37.05%363.07%
Accounts Receivable
5.481.612.931.662.3
Other Receivables
0.80.711.632.296.820.47
Receivables
6.292.312.635.228.472.77
Prepaid Expenses
1.021.120.751.571.310.42
Total Current Assets
41.0323.9821.0423.83644.82
Property, Plant & Equipment
0.50.160.220.310.280.18
Long-Term Investments
--0000
Long-Term Deferred Charges
-74.4373.575.9965.556.66
Total Assets
115.9798.5894.76100.11101.78101.66
Accounts Payable
1.150.933.091.974.341.96
Accrued Expenses
3.78-0.843.532.454.56
Current Portion of Leases
-3.832.01---
Other Current Liabilities
1.480.061.911.290.42.91
Total Current Liabilities
6.44.827.856.797.199.43
Total Liabilities
15.534.827.856.797.199.43
Common Stock
100.453.23.062.692.692.69
Additional Paid-In Capital
-192.81171.39155.19155.19155.19
Retained Earnings
-46.8137.3961.2754.9236.83
Comprehensive Income & Other
--149.05-124.92-125.83-118.21-102.47
Shareholders' Equity
100.4593.7686.9193.3294.5992.23
Total Liabilities & Equity
115.9798.5894.76100.11101.78101.66
Total Debt
-3.832.01---
Net Cash (Debt)
32.916.7215.6617.0126.2141.64
Net Cash Growth
180.38%6.80%-7.96%-35.09%-37.05%363.07%
Net Cash Per Share
1.320.680.720.791.192.04
Filing Date Shares Outstanding
25.6225.6124.4921.4921.4921.49
Total Common Shares Outstanding
25.6225.6124.4921.4921.4921.49
Working Capital
34.6319.1613.217.0128.835.39
Book Value Per Share
3.923.663.554.344.404.29
Tangible Book Value
2693.7686.9193.3294.5992.23
Tangible Book Value Per Share
1.013.663.554.344.404.29
Machinery
-1.251.271.271.140.99
Source: S&P Global Market Intelligence. Standard template. Financial Sources.